A new peer‑reviewed study is throwing up caution flags over Oregon’s statewide psilocybin program, warning that it is stretching beyond strictly medical use and that this growth may be exposing gaps in screening, reporting and equity. Researchers who dug into the program’s 2025 reporting found many people booked sessions for general wellness, shifts in perspective or "expanded consciousness," not just for diagnosed clinical conditions.
The paper, published in mid June in the International Journal of Drug Policy, used 2025 datasets from the Oregon Health Authority and concluded that the state's "supported adult use" model raises "several safety concerns." The authors, researchers affiliated with Johns Hopkins, argue that broad eligibility and a supervision system built around licensed facilitators rather than clinicians could mean people on certain medications or with serious psychiatric histories are not being screened carefully enough.
An inaugural year look at the Oregon Psilocybin Services public dashboard counted about 5,935 clients in 2025 and found that roughly a third traveled from outside Oregon for sessions, according to a peer‑reviewed report. That analysis and state reporting also show that top self‑reported motivations included general health and wellness, changing perspective and "expanded consciousness," and that under state rules products must be grown by licensed manufacturers, tested by licensed laboratories and used only during supervised sessions at licensed service centers.
"Some people reported seeking out psychedelic services for general well‑being while others reported seeking out services to treat medical or psychiatric conditions," David Yaden, an associate professor of psychedelic research at Johns Hopkins, told Lookout Eugene‑Springfield. He said the program’s overall "risk profile" looked better than he had anticipated, but he also cautioned that negative events might not be fully captured in current reporting.
Researchers Watching Real‑World Safety
Oregon Health & Science University has a five year, $3.3 million award from the National Institute on Drug Abuse to track outcomes for people who use state‑regulated psilocybin services in community settings. Todd Korthuis, a leader of that project, has said the team will publish short term findings in July, including responses up to 72 hours after treatment, as researchers build a clearer picture of safety and substance use outcomes.
Regulation, Tourism And Equity
Measure 109 created Oregon’s "supported adult use" system, and state materials focus on licensing, cultivation, testing and supervised administration rather than on medical eligibility criteria. Analysts and the statewide dashboard point to psilocybin tourism and a concentration of higher income participants as signs that access, and who actually benefits from the rollout, remain uneven across Oregon communities.
What Might Change
The Johns Hopkins authors and other researchers recommend beefing up facilitator training, tightening pre‑session clinical screening and strengthening adverse event reporting so people with medication or psychiatric vulnerabilities are less likely to slip through the cracks. State and university teams say the real world evidence emerging from these follow ups will be central for policymakers deciding whether to adjust the program or create clearer paths to bring psilocybin into medical care where that makes sense.
For Portland and other Oregon cities, the question is practical and pressing: how to keep services available while making sure facilitators, clinicians and regulators collect the data needed to protect clients. The next wave of short term reports, along with longer term tracking, is expected to give lawmakers a better read on whether Oregon’s experiment needs tighter rules or simply stronger oversight.
